| Business Summary | | Amarillo
Biosciences,
Inc.
is
a
development-stage
company
engaged
in
developing
biologics
for
the
treatment
of
human
and
animal
diseases.
The
Company
is
focusing
its
research
on
human
health
indications
for
the
use
of
low-dose,
orally
administered
natural
human
interferon
alpha
(IFNa),
particularly
for
the
treatment
of
Sjogren's
syndrome,
fibromyalgia,
hepatitis
B,
hepatitis
C
and
Behcet's
disease.
The
Company
owns
or
licenses
19
United
States
patents
relating
to
low-dose,
oral,
natural
IFNa.
Since
1992,
the
Company
has
filed
six
Investigational
New
Drug
Applications
covering
indicated
uses
for
low-dose,
oral
IFNa,
including
treatment
of
Sjogren's
syndrome
and
fibromyalgia,
with
the
United
States
Food
and
Drug
Administration.
The
Company
is
seeking
regulatory
approvals
in
certain
foreign
countries
to
test
low-dose,
oral
IFNa
in
the
treatment
of
hepatitis
B
and
C. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Amarillo
Biosciences,
Inc.,
is
a
development
stage
company.
The
Company
develops
and
markets
19
patents
and
eight
pending
applications
relating
to
low
dosage
oral
and
non-oral
natural
interferon
alpha
used
in
the
treatment
of
human
and
animal
diseases.
For
the
six
months
ended
6/30/01,
revenues
totaled
$171
thousand,
up
from
$36
thousand.
Net
loss
fell
85%
to
$376
thousand.
Results
reflect
orders
for
anhydrous
crystalline
maltose,
partially
offset
by
higher
interest
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Joseph Cummins, Ph.D., 57 Chairman,
Pres, CEO and Chief Financial Officer | $150K | Kathleen Kelleher, 51 COO,
VP-Bus. Devel. | 150K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|